Shownotes Transcript
Karen Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs’ demand means for the biopharma industry’s five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks.
Why GLP-1 Drugs Are in Demand
Competition Between Novo Nordisk and Eli Lilly
How Expanding the Conditions GLP-1 Drugs Treats Could Influence Insurance Coverage
Are Weight Loss Drugs a Threat to Snack Food Stocks?
Big Pharma’s Looming Patent Cliff
How Medicare Negotiations Impact the Pharmaceutical Industry
What is a Biologic Drug?
Upcoming Innovations in the Pharmaceutical Industry
Which BioPharma Drugs Do We Expect to Contract?
Big Pharma’s Five-Year Outlook
Biopharmaceutical Stock Picks
**Read about topics from this episode. **
2024 Biopharmaceutical Industry Landscape)
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?)
Investment Opportunities in the Biopharma Industry)
Obesity Drug Market: The Next Wave of GLP-1 Competition)
What to watch from Morningstar.
Is the Fed’s Plan to Avoid a Recession Working?)
Don't Overlook These Crucial Parts of Your Retirement Plan)
Boating Season Is Over, but Don't Overlook These Recreational Vehicle Stocks)
5 Ways to Improve America’s Retirement Savings)
Read what our team is writing:
Follow us on social media.
Facebook: https://www.facebook.com/MorningstarInc/)
X: https://x.com/MorningstarInc)
Instagram: https://www.instagram.com/morningstar)...
LinkedIn: https://www.linkedin.com/company/5161/)